372 related articles for article (PubMed ID: 19415280)
1. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
[TBL] [Abstract][Full Text] [Related]
2. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
Saif MW; Peccerillo J; Potter V
Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
[TBL] [Abstract][Full Text] [Related]
3. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
Heun J; Holen K
Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
Saif MW; Kaley K; Chu E; Copur MS
Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
[TBL] [Abstract][Full Text] [Related]
5. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports.
Langerak A; River G; Mitchell E; Cheema P; Shing M
Clin Colorectal Cancer; 2009 Jan; 8(1):49-54. PubMed ID: 19203897
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
7. Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer.
Cartwright TH; Genther R
Clin Colorectal Cancer; 2008 May; 7(3):202-3. PubMed ID: 18621639
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab.
Brugger W
Tumori; 2010; 96(3):473-7. PubMed ID: 20845811
[TBL] [Abstract][Full Text] [Related]
10. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
11. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
Cohenuram M; Saif MW
Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
[TBL] [Abstract][Full Text] [Related]
12. Role of panitumumab in the management of metastatic colorectal cancer.
Saif MW; Cohenuram M
Clin Colorectal Cancer; 2006 Jul; 6(2):118-24. PubMed ID: 16945167
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
14. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
15. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer.
Addeo R; Caraglia M; Cerbone D; Frega N; Cimmino G; Abbruzzese A; Del Prete S
Expert Rev Anticancer Ther; 2010 Apr; 10(4):499-505. PubMed ID: 20397915
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
17. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Seront E; Marot L; Coche E; Gala JL; Sempoux C; Humblet Y
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S11-4. PubMed ID: 20189054
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
You B; Chen EX
J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
[TBL] [Abstract][Full Text] [Related]
19. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ
Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985
[TBL] [Abstract][Full Text] [Related]
20. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece.
Fragoulakis V; Papagiannopoulou V; Kourlaba G; Maniadakis N; Fountzilas G
Clin Ther; 2012 Oct; 34(10):2132-42. PubMed ID: 23063374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
